<DOC>
	<DOC>NCT02739880</DOC>
	<brief_summary>The main objective of this study is to measure changes in the thickness of the vaginal lining (epithelium + underlying stroma) between 0 and 8 weeks after injection.</brief_summary>
	<brief_title>Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule</brief_title>
	<detailed_description>The secondary objectives of this study are to measure changes in the following between 0 and 8 weeks after injection: A. vaginal flora and Nugent score. B. vaginal pH. C. functional evolution via the VHI index by Gloria Bachman (state of the vaginal mucosa), pain / dyspareunia (visual analog scale) and the satisfaction concerning care viay the PGI-I questionnaire (Patient Global Impression and Improvement). D. Procollagen I and III gene expression (by PCR) and mitotic activity of the mucosa (Ki67 proliferation marker) based on biopsies.</detailed_description>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>The patient must have given her informed and signed consent The patient must be insured or beneficiary of a health insurance plan The patient is available for 8 weeks of followup The patient is menopausal (amenorrhea) for over 2 years and less than 10 years The patient has a body mass index &lt;35 The patient has sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness. The patient is participating in another study The patient is in an exclusion period determined by a previous study The patient is under judicial protection, under tutorship or curatorship The patient refuses to sign the consent It is impossible to correctly inform the patient The patient is pregnant or breastfeeding The patient is not menopausal (both clinically and biologically) The patient has a body mass index &gt; 35 The patient has a genital prolapse higher than stage 2 with a surgical indication The patient has stress incontinence with a surgical indication The patient suffers from vaginismus Presence of an untreated viral, fungal or bacterial vulvovaginal or urinary infection Hemorrhagic or neoplastic genital pathologies Existence of a hormonedependent tumor, genital bleeding of unknown origin Current treatments based on antihypertensives, steroid antiinflammatory drugs, anticoagulants, major antidepressants, aspirin Known hypersensitivity to hyaluronic acid or mannitol Known hypersensitivity to Betadine Known hypersensitivity to Lidocaine Hypersensitivity to EMLA® Previous urogynaecological vulvovaginal surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vaginal discomfort</keyword>
	<keyword>Vaginal dryness</keyword>
</DOC>